Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2025-12-30 00:00:00 ET · period of report 2025-12-29 · accession 0001423029-25-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-30 | 2025-12-29 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale+OE | $69.13 | -51.7K | 3.82M | -1% | -$3.58M |
| DM | 2025-12-30 | 2025-12-29 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $6.15 | +51.7K | 3.84M | +1% | +$318.1K |
| DM | 2025-12-30 | 2025-12-29 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $0.00 | -51.7K | 16.5K | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-29 | S | D | 16,545 | $68.69 | 3,805,926 | D | — | — | (F4) The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.10 to $69.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. (F1) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
| 2 | Common | Common Stock | 2025-12-29 | S | D | 35,181 | $69.33 | 3,822,471 | D | — | — | (F3) The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.09 to $69.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. (F1) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
| 3 | Common | Common Stock | 2025-12-29 | M | A | 16,545 | $6.15 | 3,857,652 | D | — | — | (F1) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
| 4 | Common | Common Stock | 2025-12-29 | M | A | 35,181 | $6.15 | 3,841,107 | D | — | — | (F1) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
| 5 | Derivative | Stock Option (right to buy Common Stock) | 2025-12-29 | M | D | 16,545 | $0.00 | 0 | D | $6.15 · 2016-01-01 to 2026-01-01 | 16,545 Common Stock | (F5) All options were fully vested and exercisable as of January 1, 2016. |
| 6 | Derivative | Stock Option (right to buy Common Stock) | 2025-12-29 | M | D | 35,181 | $0.00 | 16,545 | D | $6.15 · 2016-01-01 to 2026-01-01 | 35,181 Common Stock | (F5) All options were fully vested and exercisable as of January 1, 2016. |